The current consensus is that a successful HIV vaccine will need to elicit both neutralizing antibody and cellular immune responses. The antibody response should be broadly neutralizing. The feasibility of eliciting such a response is suggested by the existence of a small panel of broadly neutralizing human monoclonal antibodies (mAbs). These mAbs are valuable tools in vaccine design. They help to define conditions for antibody-mediated protection, they reveal neutralizing epitopes, they provide quality control for vaccine candidates (on which neutralizing epitopes should be expressed) and they lead directly to structures that are vaccine candidates e.g. engineered envelope molecules, peptides and carbohydrates. However, the number of broadly neutralizing mAbs is small and they are all derived from subtype B-infected donors. In order to have a larger panel of mAbs that will more effectively neutralize global HIV-1 isolates and that will stimulate vaccine research, we propose a renewed effort to generate such Abs using phage display, yeast display and memory B cell technologies. This effort is timely given a number of advances including the identification of donors with broad serum neutralizing activity and the refinement of technologies for human mAb generation and selection.
Aim 1 is to generate and characterize broadly neutralizing human mAbs from subtype A, B, and C-infected donors. 4E10 is clearly the most broadly neutralizing mAb described to date but its potency is generally only moderate. We have recently solved the structure of Fab 4E10 in complex with its peptide antigen and now propose to apply in vitro evolution techniques to improve the affinity and neutralizing characteristics of 4E10.
Aim 2 is to generate affinity-enhanced versions of 4E10 for use as entry inhibitors and as improved templates for immunogen design.
Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI033292-16
Application #
7213365
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Embry, Alan C
Project Start
1992-07-01
Project End
2010-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
16
Fiscal Year
2007
Total Cost
$583,813
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Deruaz, Maud; Moldt, Brian; Le, Khoa M et al. (2016) Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo. J Infect Dis 214:612-6
Sok, Devin; Pauthner, Matthias; Briney, Bryan et al. (2016) A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. Immunity 45:31-45
van Gils, Marit J; van den Kerkhof, Tom L G M; Ozorowski, Gabriel et al. (2016) An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat Microbiol 2:16199
Doores, Katie J; Kong, Leopold; Krumm, Stefanie A et al. (2015) Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J Virol 89:1105-18
McCoy, Laura E; Falkowska, Emilia; Doores, Katie J et al. (2015) Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathog 11:e1005110
Wang, Shenshen; Mata-Fink, Jordi; Kriegsman, Barry et al. (2015) Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell 160:785-797
Falkowska, Emilia; Le, Khoa M; Ramos, Alejandra et al. (2014) Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40:657-68
Sok, Devin; Doores, Katie J; Briney, Bryan et al. (2014) Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 6:236ra63
Moldt, Brian; Saye-Francisco, Karen; Schultz, Niccole et al. (2014) Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography. Methods 65:127-32
Garces, Fernando; Sok, Devin; Kong, Leopold et al. (2014) Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159:69-79

Showing the most recent 10 out of 138 publications